Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS) from its SEC filings: 2012 revenue $14.1 million (-15% vs the year before), net margin 211%, free cash flow $33.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2012) | $14.1 million |
| Revenue growth | -15% |
| Net income | $29.8 million |
| Net margin | 211.2% |
| Free cash flow | $33.1 million |
| Diluted EPS | $2.07 |
| Cash | $68.7 million |
| Long-term debt | $0 |
| Share count, 1 year | +3% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.